

# Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea

Mary E Money,<sup>1,2</sup> Jaroslaw Walkowiak,<sup>3</sup> Chris Virgilio,<sup>1,4</sup> Nicholas J Talley<sup>5,6</sup>

<sup>1</sup>Washington County Health Systems, Hagerstown, Maryland, USA

<sup>2</sup>Department of Internal Medicine, University of Maryland, Baltimore, Maryland, USA

<sup>3</sup>Department of Gastroenterology and Metabolism, Poznań University of Medical Sciences, Poznań, Poland

<sup>4</sup>Bernard J Dunn School of Pharmacy, Shenandoah University, Winchester, Virginia, USA

<sup>5</sup>Department of Medicine, Mayo Clinic, Mayo Clinic College of Medicine, Jacksonville, Florida, USA

<sup>6</sup>Faculty of Health, Bowman Building, University of Newcastle, Callaghan, NSW, Australia

## Correspondence to

Dr M E Money, Washington County Health Systems, 354 Mill Street, Hagerstown, MD 21740, USA; MEWaldman@aol.com

Accepted 24 September 2010  
Published Online First  
3 November 2010



This paper is freely available online under the BMJ Journals unlocked scheme, see <http://fg.bmj.com/info/unlocked.dtl>

**Objective** To evaluate the efficacy of pancrealipase (PEZ) compared with placebo in the reduction of postprandial irritable bowel syndrome-diarrhoea (IBS-D).

**Design** An intention to treat, double blind, randomised, crossover trial comparing PEZ to placebo for reduction of postprandial IBS-D. Patients had to recognise at least two different triggering foods, be willing to consume six baseline 'trigger meals' and again blinded with PEZ and placebo. Patients then chose which drug they preferred for another 25 meals.

**Setting** Outpatient internal medicine practice clinic.

**Patients** 255 patients were screened; 83 met the criteria, including 5 years of symptoms, recognised 'food triggers', no other identifiable cause for the symptoms, either a normal colonoscopy or barium enema while symptomatic and able to discontinue all anticholinergic medications. 69 patients were enrolled, 20 withdrew before randomisation, leaving 49 patients: 14 men, 35 women, mean age 52 years (SD 15.3). Over 60% had experienced symptoms for 11–30 years and 16% for more than 40 years.

**Interventions** After completing six baseline meals, patients were randomised in blocks of four to receive either identical PEZ or a placebo for another six meals, and after a washout period of time received the alternative drug.

**Main outcome measures** The primary analysis was number of patients who chose PEZ over placebo for the extended use.

**Results** Overall, 30/49 (61%) would have chosen PEZ ( $p=0.078$ ), with first drug preference for PEZ at 0.002. Among the PEZ subgroup, PEZ use compared with placebo, demonstrated improvement in all symptoms ( $p\leq 0.001$ ) for cramping, bloating, borborygmi, urge to defecate, global pain and decrease stooling with increase in stool firmness.

## What is already known about this subject?

- ▶ The irritable bowel syndrome affects close to 15% of the population and approximately one-third of these individuals have the diarrhoea condition.
- ▶ The diagnosis is made on the Rome III symptom criteria which have not been validated to exclude organic disease.
- ▶ The Rome III criteria do not include what precedes the diarrhoea as being important although 50–75% of individuals recognise that the diarrhoea occurs after eating.
- ▶ Treatment recommendations for the irritable bowel syndrome-diarrhoea condition do not routinely include pancrelipase.

## What are the new findings?

- ▶ A subgroup of patients with irritable bowel syndrome-diarrhoea responded with a reduction of their postmeal symptoms by the ingestion of pancrelipase before eating.

## How might they impact on clinical practice in the foreseeable future?

- ▶ This study may increase the recognition that these patients may have a form of maldigestion which can be improved by the supplementation of pancrelipase before consuming a meal or known 'trigger'.
- ▶ Further research may be stimulated by this pilot study.

**Conclusions** PEZ was found in a small group of patients to reduce postprandial IBS-D symptoms and deserves further evaluation.

## Introduction

At the current time, a large number of individuals are experiencing major gastrointestinal complaints after consuming certain foods, liquids, spices, etc. If diarrhoea

is present, complaints are typically diagnosed as either functional diarrhoea (if without pain) or the 'irritable bowel syndrome-diarrhoea' (IBS-D), if pain is present with the episode.<sup>1-5</sup> IBS is a condition affecting an estimated 10–15% of the US population.<sup>6,7</sup> Although not included in the widely accepted Rome criteria for IBS,<sup>7,8</sup> theories for why the symptoms occur after eating have included the following: food intolerance, food allergies or hypersensitivity, an alteration of bowel bacteria or psychosocial factors.<sup>9-11</sup>

A maldigestion or malabsorption problem is not usually considered if the food product is not related to lactose. However, a recent study conducted by Shepherd suggested that fructose malabsorption contributed to some of these complaints.<sup>12</sup> A low  $\alpha$ -glucosidase activity has been recognised as the cause of chronic osmotic diarrhoea in 21% of children diagnosed with recurrent abdominal pain associated with diarrhoea,<sup>12a</sup> and has also been recognised in adults.<sup>13-15</sup> The diagnosis of a disaccharidase deficiency which clinically causes diarrhoea after eating is only made after the objective finding of a deficiency in the concentration of the enzymes in the brush border of the small intestine or the presence of a high osmotic gap in stool water that has a pH <5. These tests are not usually performed on patients who meet the criteria for IBS-D.

Mainstream treatment recommendations for IBS-D, other than dietary modifications, have predominantly been antidiarrhoeal agents such as loperamide and diphenoxylate, tricyclic antidepressants or alosetron, a 5HT<sub>3</sub> receptor antagonist.<sup>7,16-18</sup> Other possible therapies have included clonidine,<sup>19</sup> cholestyramine,<sup>18</sup> Chinese herbal therapy,<sup>20,21</sup> cromolyn<sup>22,23</sup> and psychotherapy.<sup>24,25</sup> Antispasmodic agents such as hyoscyamine and dicyclomine are often prescribed but have not been established to be beneficial and may lose any possible benefit over time.<sup>7</sup> Pancrealipase (PEZ) has been shown to reduce bile acid malabsorption in patients with cystic fibrosis,<sup>26-28</sup> chronic pancreatitis,<sup>29</sup> fat malabsorption due to HIV<sup>30</sup> and improve digestion in normal patients consuming a fatty meal.<sup>31</sup> PEZ has recently been reported as being effective for the postprandial IBS-D condition<sup>32</sup> and among patients identified with pancreatic insufficiency who also have IBS.<sup>33</sup>  $\alpha$ -Amylase, a major component of PEZ, has been shown to augment disaccharidase activity.<sup>34,35</sup>

We hypothesised that some symptoms of IBS are due to maldigestion and/or malabsorption of certain foods. We therefore aimed to test the effectiveness of PEZ compared with placebo in the reduction of the symptoms in patients who have IBS-D after eating known triggering agents.

## Methods

### Patients

Patients were recruited by referral from local physicians and advertisements. Strict eligibility and exclusion criteria were used to establish the patient group including:

18 years or older; at least 5 years of only IBS-D symptoms before age 50 years, at least 12 times annually which had to occur within 3 h of eating at least two different triggering foods (specific for each patient); and onset before a cholecystectomy. Intolerance only to milk products was not acceptable. Patients were not eligible if they had unexplained weight loss, felt symptoms were due to medication or had been diagnosed with other gastrointestinal disorders which might explain the symptoms. A normal colonoscopy or a barium enema was required to have been completed while having postprandial symptoms. Discontinuation of gastrointestinal anticholinergic agents prior to enrolment was required and was not permitted to be restarted. Antidepressant use was allowed and any new treatments, drug therapies or dosage changes were recorded. Antidiarrhoeal drugs were permitted only after postprandial symptoms started and not before a meal. In total, 49 patients were randomised into the study (see results section below).

All patients entered into the study met the Rome II criteria for IBS: 12 consecutive or non-consecutive weeks or more in the past 12 months of abdominal discomfort or pain with two of the three features of (1) relief with defecation, (2) onset associated with a change in stool frequency and/or (3) onset associated with a change in the form (appearance) of the stool.<sup>24,36,37</sup>

In this study, patients were restricted to having only postprandial IBS-D.

### Study design

An original rigorous study design was created in an attempt to demonstrate PEZ effectiveness over placebo when taken by IBS-D patients before consuming a triggering agent. This study followed a randomised, double blind, placebo controlled, crossover design with patients serving as their own controls. It was felt that a parallel group study design would require more enrollees (see power calculation below). The study was not designed to evaluate for bacterial overgrowth or the presence of malabsorption due to limited funding.

Each patient was required to record the severity of specific postprandial symptoms that occurred after each trigger meal: cramping, bloating, borborygmi, nausea, intensity to have a bowel movement, other symptoms of sweating/chills and global pain from 0 to 10. Time of onset, duration of the episode along with stool frequency and consistency were also recorded on a specially designed meal diarrhoea form. Stool consistency was scored in a graduated fashion from normal (2 points) to watery diarrhoea (10 points) (table 1).

The meal list for patients was as follows: one non-trigger meal with a food not recognised to precipitate IBS symptoms; six baseline trigger meals with patient specific known trigger foods; 4–12 trigger meals with drug 1 (blinded: PEZ or identical placebo); another 4–12 trigger meals with drug 2 (blinded: PEZ or

**Table 1** Subjective and objective symptoms scoring for each meal

Symptoms	Subjective point score	
Cramping	0–10	
Bloating	0–10	
Borborygami	0–10	
Nausea	0–10	
Urge to have a bowel movement	0–10	
Sweating, chills	0–10	
Global abdominal pain	0–10	
<b>No of bowel movements</b>	<b>1 point each bowel movement</b>	
<b>Consistency of each stool</b>	<b>Subjective point score</b>	
Normal	2	
Soft	4	
Mushy, not formed	6	
Loose, no water	8	
Watery diarrhoea	10	
<b>Onset and duration of symptoms</b>		
<b>Time period</b>	<b>Onset points</b>	<b>Duration points</b>
0–30 min	10	2
31–60	8	4
61–90	6	6
91–120	4	8
>121	2	10

identical placebo); and 25–50 meals using their preference (drug 1 or 2 for all meals).

Each patient was permitted to return to their prior treatment or take PEZ after they completed the study. An open label follow-up was conducted 3 months after the study ended. An IBS-Specific Quality of Life (QOL) Health Questionnaire (IBS-QOL), used with permission from Patrick *et al*,<sup>38</sup> was completed by each patient at enrolment, completion and 3 months later during the open label follow-up.

#### Randomisation and concealed allocation

Only after completion of six baseline trigger meals was each participant enrolled by the study investigator and was randomised according to a computer generated blocked randomisation list using a block size of four to receive as either the first or second drug: PEZ (Viokase: lipase 8000; amylase 30 000; and protease 30 000; Axcan Pharma, Quebec, Canada) or placebo capsule (Cebocaps Blue, size 1 from Forest Pharmaceuticals (New York City, New York, USA) containing inert sucrose, starch, acacia, talc, gelatin and artificial colour). Randomisation of patients and concealed allocation were assured by the trial pharmacist who prepared the drug vials which were numbered sequentially.

#### Blinding and dosing

Both drugs were placed inside a second dark coloured space capsule, size 0. Therefore, both drugs were identical by weight and size with no perceivable taste difference. Patients were given 12 capsules for each drug period and were instructed not to open them. Patients were permitted to titrate the dose from 1 to 3 capsules

before each meal, and therefore could potentially consume up to 12 meals prior to receiving the next drug if one capsule was effective. This dosage was determined based on the clinical experience of the investigators of effective dosage of PEZ among IBS-D patients currently taking PEZ. After the first drug was used for at least four meals, patients received the alternate drug. A minimum 1 week washout period between drugs was required. Patients were instructed and encouraged to try to consume the same trigger meals for each drug but were not excluded from the study if they failed to meet this requirement. Once both drugs were tried, the patients then chose which of the two drugs (still blinded) they wanted to use for a prolonged period of up to 50 trigger meals (their choice of meals). There was no time pressure for completion of the meals at any phase of the study. Patients were also permitted to use anti-diarrhoeal agents as needed for breakthrough diarrhoea.

#### Follow-up period

Follow-up by study personnel occurred at completion of the baseline meals, after each drug use, at meal 25 of extended use and after consumption of meal 50. At every visit, each participant was interviewed for protocol adherence, including their attempt at duplication of baseline meals for drug 1 and drug 2, side effects and changes in other medical conditions or medications. Patients and investigators were unaware of the drug sequences or choice of drug for the final use until the entire trial had been concluded. Each patient, on study completion, could contact the trial pharmacist who

was permitted to disclose to the patient his/her final choice. Therefore, patients could obtain a prescription for PEZ before the conclusion of the trial from their personal physician, if desired. A 3 month follow-up was also done after completion of the study.

The Washington County Hospital Institutional Review Board approved the study and each participant gave written informed consent. Patients could withdraw from the study at any time or be removed for study protocol violations. The trial was approved by the Washington County Hospital Institutional Review Board on 18 January 2002. Enrolment was completed with 49 patients. The study concluded on 4 November 2003.

#### Statistical analysis

The primary analysis was the effectiveness of PEZ compared with placebo in reduction of postprandial symptoms among the number of individuals who chose the enzymes as the effective agent for the prolonged use period. A one way  $\chi^2$  test was used for final analysis of the number of individuals who chose placebo versus PEZ as the effective drug (primary end point) by intention to treat analysis. Independent sample t tests and two way  $\chi^2$  tests were used to determine any difference among subgroups for age, sex, number of years for IBS-D, positive family history of a similar problem, length of time for completion of the study, frequency of episodes and comparison of effectiveness of their choice of agents. One way  $\chi^2$  tests were also used to subanalyse both final groups (selected PEZ or placebo) for determining the effectiveness of the drugs compared with baseline average meal scores, enzyme meals, placebo meals and second use of the 'choice drug'. Average meal scores for each person were calculated by adding all of the symptom scores for all meals in that section and then dividing by 6 (the total number of meals).

Patient scores were not used if they consumed fewer than six meals in each section for comparison. Individual symptom scores for bloating, nausea, borborygmi, cramping, urge for defecation, sweating/chills and number of bowel movements were individually analysed by one way  $\chi^2$  tests for the enzyme subgroup comparing enzyme therapy with placebo.

The t test was used for analysis of the QOL measurements before and at the conclusion of the study for this subgroup, and for those patients who were on enzymes at the 3 month follow-up. All p values calculated were two tailed; the  $\alpha$  level of significance was set at 0.05.

#### Power calculation

Based on an estimated mean total symptom score of 100 in the placebo group with an SD of 50, it was estimated that approximately 35 patients would be needed to provide 80% power to detect a 50% change in symptoms between the drug treatments (PEZ and placebo).

## Results


### Participants

A total of 255 patients were screened for the study and 83 met the IBS-D criteria (ineligible patients included those who did not meet the Rome II criteria; had not had a colonoscopy or barium enema; had constipation IBS; did not know their specific triggering foods; and had previously been diagnosed with a medical condition causing the diarrhoea, such as inflammatory bowel disease). Of the 83 eligible patients, 69 were enrolled, but after reviewing the study requirements, 20 withdrew before being randomised. Thus 49 patients were randomised into the study (figure 1).

Patient characteristics were as follows: 14 men, 35 women, mean age 52 years (SD 15.3); 74% had symptom onset before the age of 30 years; over 60% had experienced symptoms for 11–30 years; and 16% had experienced them for more than 40 years. Thirteen patients identified anxiety or depression as a current comorbid condition, and eight were using an antidepressant (paroxetine (n=3), fluoxetine (n=1), sertraline (n=1), desipramine (n=1), venlafaxine (n=1) and amitriptyline (n=1)). Two patients were using lorazepam or alprazolam. Eight of the patients had onset of IBS symptoms at least 5 years prior to a cholecystectomy. Prior medications used by patients included: loperamide (n=30), fibre supplement (n=22), antidepressants (n=9) and anticholinergics (n=15). Prior negative studies included colonoscopy (n=42), barium enema (n=26), upper gastrointestinal examination with small bowel follow through (n=8), oesophagogastroduodenoscopy (n=10) and pancreatic function studies (n=4).

Although not a requirement for participation, 30 patients participated in additional testing for evaluation of pancreatic insufficiency and presence of coeliac disease. Testing for malabsorption, serum IgA levels and antibodies to coeliac disease was completed by one of the authors (JW at the Poznań University of Medical Sciences, Poznań, Poland). All participants had normal endomysium and tissue transglutaminase antigens values for coeliac disease<sup>39 40</sup>; 47 serum lipase measurements were evaluated and only three were less than 10% above normal (10–60 U/l).<sup>41</sup> There were 29 measurements for IgA g/l; only two were slightly elevated and none was low (normal 0.7–4.0 g/l). Of the 60 stool specimens tested for faecal elastase 1, only four registered values less than 200  $\mu\text{g/g}$  faeces, the lowest being 112  $\mu\text{g/g}$ .<sup>42</sup> Three of the four patients who had abnormally low faecal elastase selected the placebo as the 'effective agent'.

Each participant identified an average of 12 triggering foods, ranging from 2 to 23. Common food/spice triggers included: spicy seasoning (78%), lettuce (particularly iceberg) (71%), Italian food (69%), milk based products (69%), cabbage (67%), Chinese food (61%), fried food (59%), barbecue spices (49%),



**Figure 1** Consort diagram outlining the study design.

hot peppers (46%), green peppers (41%), tomatoes (45%), onions (43%), apple (37%), eggs (35%), orange juice (31%), soy sauce (31%), beef/pork (29%), garlic (24%), coffee/tea (20%) and chocolate (14%). Eighty-eight per cent had symptoms after eating out in a restaurant.

Thirty-two (69%) of the patients reported another family member with the same problem: father (n=28), mother (n=24), sister (n=20), daughter (n=4), brothers (n=3) and sons (n=3).

#### Choice of effective agent

Of the 39 patients who completed the study by using each drug for at least four trigger meals, 25 (64%) chose PEZ over placebo as the effective agent. Based on the intention to treat analysis by including those individuals who dropped out of the study as failures, 30/49 (61%) would have chosen enzymes while 19/49 (39%) would have selected the placebo ( $p=0.078$ ). Notably, the  $\chi^2$  test for selection based on first drug administered was statistically significant with the first drug preference if PEZ were received first ( $p=0.002$ ) but was not significant if the individual received placebo first ( $p=0.49$ ).

Both the placebo subgroup and the enzymes subgroup were analysed for age, gender, family history of similar problems, duration and frequency of IBS-D episodes, and time that it took to complete the study. There was no statistically significant difference in any of the above parameters between the subgroups to reflect their final choice. Loperamide use in both groups was not statistically significant and use decreased by at least 50% among patients in each group.

#### Placebo choice and patient withdrawal

Fourteen patients chose placebo over enzymes, 11 of whom had placebo as their first drug. Effectiveness of the placebo capsule was comparable to PEZ among those who chose the placebo.

Ten patients withdrew from the study. Two never completed the initial six baseline trigger meals and another six patients never completed the first drug meals: four taking placebo, two taking PEZ. Another two patients withdrew after trying the second drug, which was placebo in each case. Thus a total of six out of eight patients withdrew during a placebo drug phase.

**Table 2** Statistical analysis of enzymes compared with placebo for reduction of irritable bowel syndrome-diarrhoea symptoms in enzyme subgroup

Symptom (0–10 severe)	Mean with placebo	Mean with PEZ as No 1 drug	p Value (PEZ as No 1 drug)	Mean with PEZ as choice	p Value (PEZ as choice)
Cramping	3.50±2.73	1.42±1.88	0.006	1.09±1.69	0.001
Bloating	2.72±1.90	1.31±1.56	0.009	0.90±1.30	0.000
Borborygami	3.25±2.07	1.90±1.95	0.006	1.37±1.62	0.001
Nausea	0.53±0.92	0.26±0.53	0.057	0.21±0.53	0.034
Urgency	4.63±2.67	2.14±2.00	0.002	1.79±1.93	0.000
No of stools	1.89±1.03	0.79±0.91	0.000	0.68±0.88	0.000
Duration attack (min)	98.94±92.76	88.54±181.81	0.898	53.47±86.45	0.072
Sweating	0.72±1.18	0.34±0.63	0.181	0.28±0.60	0.106
Stool consistency	12.00±7.12	4.19±5.24	0.000	3.55±5.50	0.000
Abdominal pain	3.64±2.70	1.45±1.83	0.003	1.14±1.88	0.000

PEZ, pancreaticlipase.

**Table 3** Quality of life (QOL) comparison between baseline and completion of trial for pancreatic enzyme subgroup

QOL parameter	Baseline		Completion of trial		
	Mean	N	Mean	t	p Value
Dysphoria	45.74±28.08	22	75.71±21.97	−5.04	0.000
Interference w/activity	37.42±18.02	21	68.54±21.36	−6.14	0.000
Body image	70.07±23.35	19	86.84±15.44	−3.27	0.004
Health worry	64.68±16.65	21	82.94±13.30	−4.55	0.000
Food avoidance	20.83±20.21	22	56.06±27.96	−5.55	0.000
Social reaction	54.89±19.49	23	76.36±21.81	−4.87	0.000
Sexual	73.21±33.14	21	85.12±26.70	−2.25	0.036
Relationships	56.67±23.51	20	77.50±19.70	−5.35	0.000
Overall score	46.11±15.35	14	77.10±15.82	−5.49	0.000

### Subanalysis of enzyme subgroup

Twenty-five of the 39 patients who finished the study (64%) chose PEZ over placebo as the effective agent. Seventeen had the enzymes as the first drug and eight were given it as the second drug. Among the enzyme subgroup, PEZ resulted in a mean 60.3% reduction of IBS-D symptoms from baseline meal scores compared with a 34% change with placebo, which was statistically significant ( $p < 0.001$ ). Individual symptom comparison between enzymes and placebo for this subgroup are shown in table 2.

Improvement in symptoms ( $p \leq 0.001$ ) was identified for cramping, bloating, borborygami, urge to defecate and pain when enzymes were used in comparison with placebo. Likewise, the decrease in the number of stools and increase in stool firmness were statistically significant between placebo and second use of enzymes ( $p < 0.001$ ).

### Compliance with trigger meal consumption and severity of IBS symptoms

Average scores of the six baseline trigger meals among all participants ranged from 35 to 127 points. These scores did not follow a normal distribution pattern, reflecting the wide range of symptoms. Twenty-seven

of the 39 patients who completed the study (69%) followed the study protocol and consumed identical trigger meals for baseline, drug 1 and drug 2 more than 75% of the time. There was no difference in meal compliance between the final choice subgroups: PEZ 17/25 (68%), placebo 10/14 (71%).

### QOL at baseline and completion of study

Table 3 shows a significant improvement in IBS-QOL scores ( $p = 0.000$ – $0.036$ ) from baseline to completion of the study for the enzyme subgroup participants. A statistical comparison of IBS-QOL scores among patients choosing placebo versus enzymes was not possible due to the small sample size of the placebo subgroup.

### Safety and side effects

There were no serious adverse events during the trial. The only side effect was increased flatus ( $n = 2$  placebo;  $n = 1$  PEZ) and mild constipation ( $n = 1$  placebo;  $n = 2$  PEZ). One patient complained of increased abdominal pain and insomnia while using the placebo preparation.

### Open label 3 month follow-up

Patients were contacted 3 months after the conclusion of the trial. We located 46 (94%) patients and

**Table 4** Quality of life (QOL) comparison between baseline and 3 month follow-up of trial for patients using pancreatic enzymes open label after trial completion

QOL parameter	Baseline		3 month follow-up after trial conclusion		
	Mean	N	Mean	t	p Value
Dysphoria	50.60±26.81	31	89.42±10.35	-9.00	0.000
Interference w/activity	44.95±21.96	29	82.27±15.67	-9.32	0.000
Body image	66.59±26.37	29	90.73±10.51	-5.64	0.000
Health worry	64.44±19.57	30	87.50±12.52	-5.99	0.000
Food avoidance	23.61±21.56	30	72.78±21.43	-9.91	0.000
Social reaction	58.27±21.85	31	85.89±11.96	-7.98	0.000
Sexual	73.28±32.86	29	93.53±10.89	-3.76	0.000
Relationships	62.93±26.97	29	92.24±11.77	-7.21	0.000
Overall score	52.65±18.87	25	86.35±9.38	-9.63	0.000

31 were now using the enzymes for their postprandial symptoms (six of whom had previously picked placebo and three who had withdrawn from the study). These 31 patients had been using PEZ for an average of 6 months by the time of follow-up. Each of the 31 current users completed a global symptom severity scale of 0 (no problems) to 10 (severe problems) for their current postprandial symptoms compared with before taking the enzymes. These 31 patients scored their baseline severity as 8.6 on the scale of 0–10, but after using the enzymes they reported a severity of only 2.2. This difference was statistically significant ( $p < 0.001$ ).

In addition, these patients were asked to complete the formal IBS-QOL survey again. Their responses compared with the baseline QOL continued to show improvement beyond that recorded at the conclusion of the study (table 4).

## Discussion

The majority of patients who suffer from postprandial diarrhoea and have pain are considered to have IBS-D by the process of exclusion after meeting the Rome criteria. However, Hammer and Talley proposed that the validity of the Rome criteria in discriminating IBS from organic disease has not actually occurred.<sup>43</sup> A recent review of 25 diagnostic studies of IBS by Jellema *et al* also concluded that the symptom based criteria cannot exclude organic disease.<sup>44</sup> Among patients with symptoms suggestive of IBS-D or functional diarrhoea, the Mayo Clinic studies showed ~45% had evidence of accelerated colonic transit.<sup>45 46</sup> The cause of the accelerated colonic transit was assumed to be related to abnormal motility; however, the latter may conceivably result from nutrient malabsorption or bile acid malabsorption. In fact, Camilleri *et al* summarised several potential primary factors that may induce the symptom phenotype of IBS-D or functional diarrhoea, in which transit may be aggravated postprandially,<sup>47</sup> and in many patients symptoms may be worse after meals, as in nutrient malabsorption, gluten intolerance and bile acid

malabsorption.<sup>48</sup> Consequently, treatment options have been limited since the underlying aetiology has not been established and most patients resort to using antimotility agents by default.

This study was spearheaded by the observation that the majority of patients with postprandial IBS-D in a large internal medicine practice reported a major improvement in symptoms when prescribed PEZ to use before meals (MEM, personal communication). This observation led to the development of the novel pilot trial presented in this report.

The study protocol attempted to reproduce the clinical benefit reported by requiring each participant to knowingly attempt to trigger an IBS attack by ingesting the foods or substances multiple times that they believed caused their symptoms while using the blinded drugs. The study design was unfortunately too demanding, resulting in a large dropout rate and limiting the statistical findings.

Even in spite of this, 25 patients did choose PEZ compared with 14 for placebo as the effective agent among the 39 who completed the study. By intention to treat analysis, which includes those patients who dropped out, 30/49 (61%) would have chosen enzymes while 19/49 (39%) would have selected the placebo, trending towards a definite benefit for enzymes although the  $p$  value did not reach statistical significance ( $p = 0.078$ ).

On a global symptom score from 0 to 10, patients reported a 74% reduction in their perceived postprandial symptoms on the enzymes compared with symptoms before starting the study. The enzymes had been used an average of 6 months by the time of the final interview in 2004. We found a significant improvement in the IBS-QOL scores compared with baseline among these long term IBS-D sufferers. Moreover, statistical significance was achieved in each IBS-QOL subcategory.

Although there were significant limitations noted with this pilot study, including a high dropout rate, inability to exclude a first drug effect to account for the number of patients choosing PEZ, difficulty measuring the effectiveness of a drug based on specific symptoms reduction and the potential inability of patients

to identify their triggers accurately or willingness to consume the most triggering agent, it did demonstrate that there was a trend towards significant reduction of IBS-D symptoms with pancreatic enzymes.

The food triggers identified by the patients and the rapidity of the postmeal syndrome suggest a possible relative disaccharidase deficiency. Scientific evidence has demonstrated that the disaccharidase enzymes can be downregulated by medications and food substances. Quercetin, which is found in multiple foods, including onions, is five times more potent than the  $\alpha$ -glucosidase inhibitor, acarbose.<sup>49 50</sup> (Onions were identified by 43% of the participants as a trigger for the postprandial diarrhoea syndrome.) Research has been extensive on locating  $\alpha$ -glucosidase inhibitors to treat diabetes which have included Vietnamese edible plants<sup>51</sup> and chamomile tea,<sup>52</sup> to name only a few items. Therefore, it is possible that the actual food substance that a person is ingesting might result in a transient inhibition of the disaccharidases resulting in the digestive disorder associated with that meal or patients have a relative disaccharidase deficiency. Since  $\alpha$ -amylase has been shown to potentiate the action of disaccharidases,<sup>34 35</sup> the amylase component or other enzymes in PEZ may be ameliorating this effect when taken before the ingestion of the triggering substance.

Further studies are needed to study the effectiveness of PEZ compared with placebo in patients with this condition. In the meantime, however, because PEZ are relatively safe, patients might be offered them as a therapeutic option if their symptoms occur predominantly after meals.

**Acknowledgements** The authors thank Raymond Morgan, PhD, for editing support; WH Money, PhD, for preliminary statistical analysis; Community Foundation of Washington County, MD, for research effort support; and David Whitcomb, MD, PhD.

**Funding** Pancreatic enzymes were supplied at no cost by Axcan Pharma. The company also funded the statistical analysis and initial editing but was not involved in the planning or conduct of the trial. Small unrestricted grants were received from the Medical Staff of the Washington County Hospital, the Washington County Health Systems Community Health Council Fund and the Hagerstown Medical Laboratory. Individual donations were also received from G Manger, MD, M Elliott, J Hershey and J Morgan.

**Competing interests** MEM—Axcan Pharma study support only: Viokase medication; funding for statistical analysis and editing of the paper. NT—Novartis, Takeda, GlaxoSmithKline, Dynogen, Tioga.

**Ethical approval** This randomised controlled trial was approved by the Washington County Hospital Institutional Review Board on 18 January 2002.

**Provenance and peer review** Not commissioned; externally peer reviewed.

## References

1. Friedman G. Diet and the irritable bowel syndrome. *Gastroenterol Clin North Am* 1991;20:313–24.
2. Gertner D, Powell-Tuck J. Irritable bowel syndrome and food intolerance. *Practitioner* 1994;238:499–502, 504.
3. Cerrato PL. A dietary remedy for irritable bowel syndrome. *RN* 1987;50:65–6.
4. Nanda R, James R, Smith H, *et al.* Food intolerance and the irritable bowel syndrome. *Gut* 1989;30:1099–104.
5. Simrén M, Månsson A, Langkilde AM, *et al.* Food-related gastrointestinal symptoms in the irritable bowel syndrome. *Digestion* 2001;63:108–15.
6. Hungin AP, Chang L, Locke GR, *et al.* Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. *Aliment Pharmacol Ther* 2005;21:1365–75.
7. Tillisch K, Chang L. Diagnosis and treatment of irritable bowel syndrome: state of the art. *Curr Gastroenterol Rep* 2005;7:249–56.
8. Camilleri M, Heading RC, Thompson WG. Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. *Aliment Pharmacol Ther* 2002;16:1407–30.
9. Alpers DH. Diet and irritable bowel syndrome. *Curr Opin Gastroenterol* 2006;22:136–9.
10. Floch MH, Narayan R. Diet in the irritable bowel syndrome. *J Clin Gastroenterol* 2002;35(1 Suppl):S45–52.
11. Zar S, Kumar D, Benson MJ. Food hypersensitivity and irritable bowel syndrome. *Aliment Pharmacol Ther* 2001;15:439–49.
12. Shepherd SJ, Parker FC, Muir JG, *et al.* Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. *Clin Gastroenterol Hepatol* 2008;6:765–71.
- 12a. Karnsakul W, Luginbuehl U, Hahn D, *et al.* Disaccharidase activities in dyspeptic children: biochemical and molecular investigations of maltase-glucoamylase activity. *J Pediatr Gastroenterol Nutr* 2002;35:551–6.
13. Herber R. Disaccharidase deficiency in health and disease. *Calif Med* 1972;116:23–37.
14. Bayless TM, Christopher NL. Disaccharidase deficiency. *Am J Clin Nutr* 1969;22:181–90.
15. Gudmand-Høyer E. The clinical significance of disaccharide maldigestion. *Am J Clin Nutr* 1994; 59(3 Suppl):735–41S.
16. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. *Br J Clin Pharmacol* 2003;56:362–9.
17. Farthing MJ. Treatment options in irritable bowel syndrome. *Best Pract Res Clin Gastroenterol* 2004;18:773–86.
18. Mearin F. Pharmacological treatment of the irritable bowel syndrome and other functional bowel disorders. *Digestion* 2006;73(Suppl 1):28–37.
19. Chang HY, Kelly EC, Lembo AJ. Current gut-directed therapies for irritable bowel syndrome. *Curr Treat Options Gastroenterol* 2006;9:314–23.
20. Bensoussan A. Establishing evidence for Chinese medicine: a case example of irritable bowel syndrome. *Zhonghua Yi Xue Za Zhi (Taipei)* 2001;64:487–92.
21. Bensoussan A, Talley NJ, Hing M, *et al.* Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. *JAMA* 1998;280:1585–9.



22. **Stefanini GF**, Saggiaro A, Alvisi V, *et al.* Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients. *Scand J Gastroenterol* 1995;30:535–41.
23. **Stefanini GF**, Prati E, Albini MC, *et al.* Oral disodium cromoglycate treatment on irritable bowel syndrome: an open study on 101 subjects with diarrheic type. *Am J Gastroenterol* 1992;87:55–7.
24. **Thompson WG**. The treatment of irritable bowel syndrome. *Aliment Pharmacol Ther* 2002;16:1395–406.
25. **Blanchard EB**, Scharff L. Psychosocial aspects of assessment and treatment of irritable bowel syndrome in adults and recurrent abdominal pain in children. *J Consult Clin Psychol* 2002;70:725–38.
26. **Stern RC**, Eisenberg JD, Wagener JS, *et al.* A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. *Am J Gastroenterol* 2000;95:1932–8.
27. **Weber AM**, Roy CC, Chartrand L, *et al.* Relationship between bile acid malabsorption and pancreatic insufficiency in cystic fibrosis. *Gut* 1976;17:295–9.
28. **Boyle BJ**, Long WB, Balistreri WF, *et al.* Effect of cimetidine and pancreatic enzymes on serum and fecal bile acids and fat absorption in cystic fibrosis. *Gastroenterology* 1980;78:950–3.
29. **Dutta SK**, Anand K, Gadacz TR. Bile salt malabsorption in pancreatic insufficiency secondary to alcoholic pancreatitis. *Gastroenterology* 1986;91:1243–9.
30. **Carroccio A**, Guarino A, Zuin G, *et al.* Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients. *Aliment Pharmacol Ther* 2001;15:1619–25.
31. **Suarez F**, Levitt MD, Adshead J, *et al.* Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. *Dig Dis Sci* 1999;44:1317–21.
32. **Money ME**, Hofmann AF, Hagey LR, *et al.* Treatment of irritable bowel syndrome-diarrhea with pancrelipase or colesvelam and association with steatorrhea. *Pancreas* 2009;38:232–3.
33. **Leeds JS**, Hopper AD, Sidhu R, *et al.* Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. *Clin Gastroenterol Hepatol* 2010;8:433–8.
34. **Nichols BL**, Quezada-Calvillo R, Robayo-Torres CC, *et al.* Mucosal maltase-glucoamylase plays a crucial role in starch digestion and prandial glucose homeostasis of mice. *J Nutr* 2009;139:684–90.
35. **Quezada-Calvillo R**, Robayo-Torres CC, Opekun AR, *et al.* Contribution of mucosal maltase-glucoamylase activities to mouse small intestinal starch alpha-glucogenesis. *J Nutr* 2007;137:1725–33.
36. **Thompson WG**, Longstreth GF, Drossman DA, *et al.* Functional bowel disorders and functional abdominal pain. *Gut* 1999;45(Suppl 2):II43–7.
37. **Leombo TJ**, Fink RN. Clinical assessment of irritable bowel syndrome. *J Clin Gastroenterol* 2002;35(1 Suppl):S31–6.
38. **Patrick DL**, Drossman DA, Frederick IO, *et al.* Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. *Dig Dis Sci* 1998;43:400–11.
39. **Schlumberger W**, Olbrich S, Muller-Kunert E, *et al.* Antikörper gegen Gliadin und gegen Endomysium zur Diagnose der Gluten-sensitiven Enteropathie. *J Lab Med* 1993;17:246.
40. **Chorzelski TP**, Beutner EH, Sulej J, *et al.* IgA anti-endomysium antibody. A new immunological marker of dermatitis herpetiformis and coeliac disease. *Br J Dermatol* 1984;111:395–402.
41. **Imamura S**, Hirayama T, Arai T, *et al.* An enzymatic method using 1,2 diglyceride for pancreatic lipase in serum. *Clin Chem* 1989;35:1126.
42. **Scheefers-Borchel U**, Scheefers H, Arnold R, *et al.* Pankreatische Elastase-1: Parameter für die chronische und akute Pankreatitis. *Lab Med* 1992;16:427–74.
43. **Hammer J**, Talley NJ. Diagnostic criteria for the irritable bowel syndrome. *Am J Med* 1999;107:5S–11S.
44. **Jellema P**, van der Windt DA, Schellevis FG, *et al.* Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. *Aliment Pharmacol Ther* 2009;30:695–706.
45. **Camilleri M**, McKinzie S, Busciglio I, *et al.* Prospective study of motor, sensory, psychologic, and autonomic functions in patients with irritable bowel syndrome. *Clin Gastroenterol Hepatol* 2008;6:772–81.
46. **Manabe N**, Wong BS, Camilleri M, *et al.* Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. *Neurogastroenterol Motil* 2010;22:293–e82.
47. **Deiteren A**, Camilleri M, Burton D, *et al.* Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. *Dig Dis Sci* 2010;55:384–91.
48. **Camilleri M**. Do the symptom-based, Rome criteria of irritable bowel syndrome lead to better diagnosis and treatment outcomes? The con argument. *Clin Gastroenterol Hepatol* 2010;8:129.
49. **Slimestad R**, Fossen T, Vågen IM. Onions: a source of unique dietary flavonoids. *J Agric Food Chem* 2007;55:10067–80.
50. **Li YQ**, Zhou FC, Gao F, *et al.* Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of alpha-glucosidase. *J Agric Food Chem* 2009;57:11463–8.
51. **Mai TT**, Thu NN, Tien PG, *et al.* Alpha-glucosidase inhibitory and antioxidant activities of Vietnamese edible plants and their relationships with polyphenol contents. *J Nutr Sci Vitaminol* 2007;53:267–76.
52. **Kato A**, Minoshima Y, Yamamoto J, *et al.* Protective effects of dietary chamomile tea on diabetic complications. *J Agric Food Chem* 2008;56:8206–11.